Lisinopril vs. Losartan: Which Blood Pressure Drug Is Right for You?

How Each Drug Works

Lisinopril blocks angiotensin-converting enzyme, stopping the conversion of angiotensin I to angiotensin II. Losartan blocks the AT1 receptor where angiotensin II docks. The net blood-pressure effect is similar, but the upstream versus downstream distinction matters clinically. ACE inhibitors let bradykinin accumulate, which is why 5 to 20 percent of patients develop a persistent dry cough, and why angioedema risk is higher compared with ARBs. [1]

Losartan, by contrast, leaves bradykinin metabolism untouched. It also has a mild uricosuric effect, lowering serum uric acid by roughly 25 percent. That secondary property makes losartan the preferred renin-angiotensin system (RAS) blocker for patients who also carry a gout diagnosis. [2]

Both drugs cause efferent arteriolar dilation in the kidney, which reduces intraglomerular pressure. This is the mechanism behind their renal-protective effects. An acute rise in serum creatinine of up to 30 percent after starting either drug is expected and acceptable; a rise above 30 percent should prompt nephrology referral and drug reassessment.

Blood Pressure Efficacy: Head-to-Head Data

At guideline-recommended doses, lisinopril and losartan produce nearly identical reductions in systolic blood pressure. The CATCH trial assigned 177 hypertensive patients with left-ventricular hypertrophy (LVH) to lisinopril 20 mg or losartan 50 mg for 12 months and found both agents regressed LVH to a similar degree, with no statistically significant difference in blood-pressure reduction between the two groups. [3]

The 2017 ACC/AHA hypertension guideline (now defining hypertension as systolic blood pressure at or above 130 mmHg) treats ACE inhibitors and ARBs as interchangeable first-line agents for most patients, explicitly noting that combining them is contraindicated due to increased risk of hypotension, hyperkalemia, and renal failure. [4]

Neither drug significantly affects resting heart rate. When rate control matters alongside blood pressure management, adding metoprolol or carvedilol is the usual next step. That choice has its own nuance: carvedilol provides alpha-1 blockade and is metabolically neutral (or slightly favorable) in insulin-resistant patients, whereas metoprolol succinate has stronger mortality data in systolic heart failure from the MERIT-HF trial (N=3,991 to 34% relative reduction in all-cause mortality). [5]

Kidney Protection: Where Losartan Has a Clearer Edge

Both drugs protect the kidney in diabetic and non-diabetic CKD. Losartan carries the stronger landmark dataset for type 2 diabetic nephropathy. The RENAAL trial (N=1,513) showed losartan 50 to 100 mg daily reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16 percent compared with placebo, and cut the risk of first hospitalization for heart failure by 32 percent (P<0.001). [6]

Lisinopril's comparable kidney data comes largely from the EUCLID trial in type 1 diabetes and from multiple meta-analyses. A 2001 meta-analysis in the Annals of Internal Medicine covering 1,860 patients with non-diabetic CKD found ACE-inhibitor therapy cut the risk of ESRD by 31 percent versus placebo (P<0.001). [7]

For patients with both CKD and proteinuria above 300 mg/g creatinine, current KDIGO 2022 guidelines recommend starting an ACE inhibitor or ARB regardless of whether blood pressure is above target, underscoring that the renal benefit is partially independent of blood-pressure lowering itself. [8]

Heart Failure Outcomes

Lisinopril holds more direct heart-failure mortality data. The ATLAS trial (N=3,164, systolic heart failure with ejection fraction <30%) compared low-dose lisinopril (2.5 to 5 mg daily) with high-dose lisinopril (32.5 to 35 mg daily). High-dose therapy reduced the combined endpoint of all-cause mortality and hospitalization by 12 percent (P=0.002), with only a modest increase in dizziness and renal dysfunction. [9]

Losartan was tested in heart failure in the ELITE II trial (N=3,152) against captopril. Losartan did not show superiority; all-cause mortality was 11.7 percent with losartan vs. 10.4 percent with captopril. [10] The 2022 AHA/ACC heart-failure guideline consequently lists ACE inhibitors as first-line RAAS therapy for HFrEF, with ARBs reserved for patients who cannot tolerate ACE inhibitors due to cough or angioedema. [11]

Side Effects Compared

Dry cough. Bradykinin accumulation under lisinopril produces a dry, tickling cough in 5 to 20 percent of patients, with higher rates in East Asian populations (up to 30 to 40 percent). Switching to losartan resolves this in nearly all cases. [1]

Angioedema. Lisinopril causes angioedema in approximately 0.1 to 0.7 percent of patients. Risk is three to five times higher in Black patients. Losartan carries a much lower risk but is not risk-free because some angioedema is bradykinin-independent. A prior episode of ACE-inhibitor angioedema is an absolute contraindication to re-challenge with any ACE inhibitor. [12]

Hyperkalemia. Both drugs raise serum potassium by roughly 0.1 to 0.5 mEq/L. Risk escalates with declining eGFR, concomitant potassium-sparing diuretics (spironolactone, eplerenone), or NSAID use. Baseline and follow-up potassium checks at 1 to 2 weeks after initiation are standard of care. [4]

Erectile function. Losartan may modestly improve erectile function in hypertensive men, an effect seen in a small RCT (N=47) where the International Index of Erectile Function score improved by 6.8 points on losartan versus 2.0 points on amlodipine (P<0.05). [13] Lisinopril is largely neutral on erectile function.

First-dose hypotension. Both drugs carry this risk, most pronounced in volume-depleted patients (recent diuretic use, low-sodium diet, diarrhea). Starting at half the target dose and titrating over 2 to 4 weeks mitigates this.

The Cardiometabolic Picture: ApoB, Statins, and Anticoagulants

Blood pressure is one variable in a multifactorial risk equation. Patients on lisinopril or losartan often carry other cardiometabolic diagnoses requiring additional therapies, and the interactions matter.

ApoB versus LDL. Standard lipid panels report LDL-cholesterol concentration, but ApoB counts the actual number of atherogenic particles. Each VLDL, IDL, and LDL particle carries exactly one ApoB molecule. Discordance between LDL-C and ApoB occurs in roughly 20 to 30 percent of metabolic-syndrome patients, typically because small dense LDL particles inflate particle count without proportionately raising LDL-C mass. A 2021 analysis in JAMA Cardiology found that among patients with LDL-C <70 mg/dL on statin therapy, elevated ApoB above 80 mg/dL independently predicted a 31 percent higher rate of major adverse cardiovascular events. [14] ACE inhibitors and ARBs do not directly affect ApoB or LDL-C, so statin therapy remains the primary tool for particle reduction.

Statin vs. bempedoic acid. High-intensity statins (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg) remain the first-line pharmacotherapy to lower ApoB and LDL. For patients who are statin-intolerant, bempedoic acid 180 mg daily inhibits ATP-citrate lyase upstream of HMG-CoA reductase. The CLEAR Outcomes trial (N=13,970) showed bempedoic acid reduced major adverse cardiovascular events by 13 percent versus placebo (HR 0.87, P=0.004) in statin-intolerant patients with high cardiovascular risk. [15] Bempedoic acid raises uric acid and is therefore a poor pairing with losartan in gout-prone patients, where the uricosuric benefit of losartan could partially offset but not reliably neutralize the uric-acid rise.

Apixaban versus rivaroxaban. Many hypertensive patients also carry atrial fibrillation and require anticoagulation. Apixaban (Eliquis) and rivaroxaban (Xarelto) are both factor Xa inhibitors, but trial-level differences matter. ARISTOTLE (N=18,201) showed apixaban reduced stroke or systemic embolism by 21 percent versus warfarin and reduced all-cause mortality by 11 percent (P=0.047), with significantly less major bleeding. [16] Rivaroxaban in ROCKET-AF (N=14,264) showed non-inferiority to warfarin for stroke prevention but with no mortality advantage. [17] Neither drug interacts with lisinopril or losartan at the pharmacokinetic level, but both carry additive hypotension risk with RAS blockers, especially in elderly patients.

Practical titration framework for the lisinopril-vs-losartan decision:

1. Start with lisinopril 10 mg daily if the patient has heart failure with reduced ejection fraction, is post-myocardial infarction, or if cost is the dominant concern.
2. Switch to losartan 50 mg daily (titrate to 100 mg as tolerated) if cough develops, angioedema has occurred, or the patient has type 2 diabetic nephropathy with proteinuria.
3. Add losartan's uricosuric benefit to the selection calculus in patients with concurrent hyperuricemia or gout on allopurinol.
4. Check potassium and creatinine at baseline and again at 1 to 2 weeks after any dose change.
5. If ApoB remains above 80 mg/dL despite LDL-C control, escalate lipid therapy independently; RAS blockers do not substitute.

Special Populations

Pregnancy. Both drugs are absolutely contraindicated beginning in the second trimester due to fetal renal dysgenesis, oligohydramnios, and neonatal death. The FDA issued a black-box warning covering all RAS-blocking agents in pregnancy. Women of childbearing age should use reliable contraception or transition to methyldopa or nifedipine if pregnancy is planned. [18]

Black patients. RAS-blocker monotherapy is less effective as initial treatment in Black patients due to lower baseline renin activity in this population. The ALLHAT trial (N=42,418) demonstrated that chlorthalidone and amlodipine outperformed lisinopril for stroke and cardiovascular endpoints in Black participants specifically. [19] Current ACC/AHA guidelines recommend a thiazide-type diuretic or long-acting calcium-channel blocker as preferred monotherapy in Black patients without compelling indications (CKD, heart failure, diabetes) that favor a RAS blocker. [4]

Elderly patients (age 65 and above). Both drugs require slower titration. The risk of first-dose hypotension and subsequent falls is clinically significant. Starting at 2.5 to 5 mg of lisinopril or 25 mg of losartan with weekly rather than biweekly uptitration is reasonable.

Bilateral renal artery stenosis. Both drugs are contraindicated here. Efferent arteriolar dilation in the setting of fixed afferent obstruction can precipitate acute kidney injury. Doppler ultrasound before starting therapy is warranted when clinical suspicion is present.

Drug Interactions

Both ACE inhibitors and ARBs raise potassium and lower blood pressure. Adding spironolactone (common in resistant hypertension and HFrEF) to either drug demands close potassium monitoring. NSAIDs blunt the antihypertensive effect of both drug classes by roughly 3 to 5 mmHg systolic and increase the risk of acute kidney injury. Lithium clearance falls with RAS blockers, raising lithium toxicity risk; serum lithium levels should be checked within 7 days of starting either agent in patients on mood stabilizers. [20]

Losartan is metabolized by CYP2C9. Fluconazole and other strong CYP2C9 inhibitors may increase losartan exposure by 50 percent or more. Lisinopril is not hepatically metabolized, making it the safer choice when significant CYP2C9 drug interactions are present.

Monitoring After Starting Either Drug

| Timepoint | Test | |-----------|------| | Baseline | BMP (creatinine, potassium, eGFR), blood pressure both arms | | 1 to 2 weeks after initiation or dose increase | Repeat BMP, standing blood pressure | | 3 months | BMP, blood pressure at goal assessment | | Annually | BMP, urine albumin-to-creatinine ratio, lipid panel with ApoB if at high CV risk |

A creatinine rise of more than 30 percent or potassium above 5.5 mEq/L should prompt dose reduction or discontinuation and nephrology consultation.